Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article in Health Affairs Forefront] explores how more thorough systems thinking can yield more realistic evaluations of the impact of new therapies.

Read the article on